We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Finger Prick Blood Test to Enable Early Alzheimer’s Detection

By LabMedica International staff writers
Posted on 20 Nov 2024

A new approach using a quick finger prick and a few drops of blood on a card that can be sent in regular mail could make Alzheimer’s testing much more accessible worldwide. More...

The new test involves collecting one or two drops of blood from a finger prick onto a special card that immediately separates the blood cells from the plasma. After about 15 minutes, once the card has dried, it is mailed to a laboratory where high-sensitivity techniques are used for analysis. The biomarkers used in this test have been developed over a long period and have demonstrated strong performance, first in cerebrospinal fluid, then in venous blood samples, and now in blood taken from superficial vessels in the finger.

The European study, led by researchers at the University of Gothenburg (Gothenburg, Sweden), included capillary blood samples from 203 participants who took the finger prick test at one of five memory clinics across Europe. The test kits were then mailed to the neurochemistry department at the University of Gothenburg, where biomarkers for Alzheimer’s, such as pTau217, were analyzed. This test could be available for use within a few years. Another European study is already in progress to assess whether the test can be self-administered, allowing individuals to perform the finger prick and send the sample to the lab without the need for healthcare personnel.

This development comes at a time when Alzheimer’s treatments are advancing, with the drug lecanemab already approved in several countries outside the EU. Early detection is crucial for the effectiveness of these treatments. The test may also open up new opportunities for research into Alzheimer’s disease, including its genetic profile and global prevalence. However, researchers stress that this test is not intended for widespread population screening. The World Health Organization (WHO) currently advises against general screening for Alzheimer’s disease, as treatment options have traditionally been limited, making such screenings ethically questionable.

“The simple capillary blood test works almost as well as venous samples, but unlike traditional blood tests, this new test does not require transport on dry ice,” said Hanna Huber, one of the study’s authors. “This could significantly increase accessibility to Alzheimer’s testing in countries and regions lacking the infrastructure needed for high-sensitivity analyses.”


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.